TY - JOUR T1 - Impact of dogs with deltamethrin-impregnated collars on prevalence of visceral leishmaniasis JF - medRxiv DO - 10.1101/19011577 SP - 19011577 AU - Mondal Hasan Zahid AU - Christopher M. Kribs Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/11/12/19011577.abstract N2 - Leishmaniasis is a vector borne zoonosis which is classified as a neglected tropical disease. Among the three most common forms of the disease, Visceral Leishmaniasis (VL) is the most threatening to human health, causing 20,000 to 30,000 deaths worldwide each year. Areas where VL is mostly endemic have unprotected dogs in community and houses. The presence of dogs usually increases VL risk for humans since dogs are the principal reservoir host for the parasite of the disease. Based on this fact, most earlier studies consider culling dogs as a control measure for the spread of VL. A more recent control measure has been the use of deltamethrin-impregnated dog collars (DIDCs) to protect both humans and dogs by putting DIDCs on dogs neck. The presence of dogs helps to grow the sandfly population faster by offering a more suitable blood-meal source. On the other hand, the presence of DIDCs on dogs helps to reduce sandfly population by the lethality of deltamethrin insecticide. This study brings an ecological perspective to this public health concern, aiming to understand the impact of an additional host (here, protected dogs) on disease risk to a primary host (here, humans). To answer this question, we compare two different settings: a community without dogs, and a community with dogs protected with DIDC. Our analysis shows the presence of protected dogs can reduce VL infection risk in humans. However, this disease risk reduction depends on dogs’ tolerance for sandfly bites.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNon-funded workAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A ER -